Apyx Medical CorporationAPYXNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank56
3Y CAGR+22.5%
5Y CAGR-14.2%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
+22.5%/yr
vs +14.5%/yr prior
5Y CAGR
-14.2%/yr
Recent acceleration
Acceleration
+8.0pp
Accelerating
Percentile
P56
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 28.45% |
| Q3 2025 | -186.78% |
| Q2 2025 | -75.64% |
| Q1 2025 | 76.10% |
| Q4 2024 | 33.85% |
| Q3 2024 | -2.56% |
| Q2 2024 | 31.73% |
| Q1 2024 | -1284.50% |
| Q4 2023 | -112.39% |
| Q3 2023 | 176.17% |
| Q2 2023 | -157.95% |
| Q1 2023 | 58.48% |
| Q4 2022 | 15.49% |
| Q3 2022 | 8.72% |
| Q2 2022 | -29.97% |
| Q1 2022 | -2211.21% |
| Q4 2021 | 105.94% |
| Q3 2021 | 27.99% |
| Q2 2021 | -143.96% |
| Q1 2021 | -101.77% |
| Q4 2020 | 61.12% |
| Q3 2020 | 47.95% |
| Q2 2020 | 32.15% |
| Q1 2020 | -119.08% |
| Q4 2019 | 31.74% |
| Q3 2019 | 9.98% |
| Q2 2019 | -18.60% |
| Q1 2019 | 74.48% |
| Q4 2018 | -1475.04% |
| Q3 2018 | -101.40% |
| Q2 2018 | 48.29% |
| Q1 2018 | -251.57% |
| Q4 2017 | 235.12% |
| Q3 2017 | 49.72% |
| Q2 2017 | 61.82% |
| Q1 2017 | -418.01% |
| Q4 2016 | -725.29% |
| Q3 2016 | 176.99% |
| Q2 2016 | 95.02% |
| Q1 2016 | -122.04% |